HRP20220865T1 - T stanični receptori - Google Patents
T stanični receptori Download PDFInfo
- Publication number
- HRP20220865T1 HRP20220865T1 HRP20220865TT HRP20220865T HRP20220865T1 HR P20220865 T1 HRP20220865 T1 HR P20220865T1 HR P20220865T T HRP20220865T T HR P20220865TT HR P20220865 T HRP20220865 T HR P20220865T HR P20220865 T1 HRP20220865 T1 HR P20220865T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- tcr
- Prior art date
Links
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims 189
- 108091008874 T cell receptors Proteins 0.000 title claims 188
- 125000003275 alpha amino acid group Chemical group 0.000 claims 170
- 230000004927 fusion Effects 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 108700026244 Open Reading Frames Proteins 0.000 claims 4
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 claims 3
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 claims 3
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 claims 3
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 claims 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000833 heterodimer Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 108010012015 GVYDGREHTV Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (20)
1. T stanični receptor (TCR) koji ima svojstvo vezivanja za GVYDGREHTV (SEQ ID NO: 1) HLA-A*02 kompleks i koji sadrži varijabilnu domenu TCR alfa lanca i varijabilnu domenu TCR beta lanca, pri čemu:
(a) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:17; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:28;
(b) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:25;
(c) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:28;
(d) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:20; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:28;
(e) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(f) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:27;
(g) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(h) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:23; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(i) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:46; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(j) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:47; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(k) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:48; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(l) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:49; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(m) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 50; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(n) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:51; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(o) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:20; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:65;
(p) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:66;
(q) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:67;
(r) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:68;
(s) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:69;
(t) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:70;
(u) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 52; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(v) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:53; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(w) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 54; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(x) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:55; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(y) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:56; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(z) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:57; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(aa) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:58; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(bb) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:59; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(cc) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:60; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(dd) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:71;
(ee) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca obuhvata aminokiselinsku sekvencu SEQ ID NO:72;
(ff) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:73;
(gg) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:74;
(hh) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:75;
(ii) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:76;
(jj) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:77;
(kk) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:78; ili
(ll) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:79.;
2. TCR prema zahtjevu 1, naznačen time što varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24 i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29.;
3. TCR prema zahtjevu 1, naznačen time što varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22 i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26.;
4. TCR prema zahtjevu 1, koji je
(a) alfa-beta heterodimer, koji ima sekvencu konstantne domene alfa lanca TRAC i sekvencu konstantne domene beta lanca TRBC1 ili TRBC2, ili
(b) u formatu jednog lanca tipa Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, Vα-L-Vβ-Cβ,
pri čemu su Vα i Vβ TCR α i β varijabilne regije respektivno, Cα i Cβ su TCR α i β konstantni regioni respektivno, a L je sekvenca linkera.;
5. TCR prema zahtjevu 4, koji je alfa-beta heterodimer, pri čemu su sekvence konstantne domene alfa i beta lanca modifikovane skraćivanjem ili supstitucijom da bi se izbrisala nativna disulfidna veza između Cys4 egzona 2 od TRAC i Cys2 egzona 2 od TRBC1 ili TRBC2, i/ili izborno, sekvenca(e) konstantne domene alfa i/ili beta lanca su modificirane supstitucijom cisteinskih ostataka za Thr 48 TRAC i Ser 57 TRBC1 ili TRBC2, pri čemu navedeni cisteini formiraju ne-nativnu disulfidnu vezu između alfa i beta konstantnih domena TCR.;
6. TCR prema bilo kojem prethodnom zahtjevu koji je povezan sa obilježivačem koji se može detektirati, terapeutskim agensom ili grupom koja modificira PK, izborno pri čemu je anti-CD3 antitijelo kovalentno vezano za C- ili N-terminus alfa ili beta lanca TCR, izborno pri čemu je anti-CD3 antitijelo kovalentno vezano za C- ili N-terminus beta lanca TCR preko linkerske sekvence, izborno pri čemu je linkerska sekvenca izabrana iz grupe koja se sastoji od GGGGS (SEQ ID NO: 30), GGGSG (SEQ ID NO: 31), GGSGG (SEQ ID NO: 32), GSGGG (SEQ ID NO: 33), GSGGGP (SEQ ID NO: 34), GGEPS (SEQ ID NO: 35), GGEGGGP (SEK ID BR: 36), i GGEGGGSEGGGS (SEQ ID NO: 37).;
7. TCR-anti-CD3 fuzijska molekula u kojoj:
(a) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:17; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:28;
(b) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:25;
(c) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:28;
(d) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:20; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:28;
(e) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(f) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:27;
(g) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(h) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:23; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(i) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:46; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(j) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:47; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(k) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:48; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(l) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:49; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(m) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 50; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(n) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:51; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:29;
(o) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:20; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:65;
(p) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:66;
(q) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:67;
(r) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:68;
(s) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:69;
(t) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:24; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:70;
(u) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 52; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(v) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:53; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(w) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 54; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(x) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:55; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(y) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:56; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(z) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:57; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(aa) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:58; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(bb) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:59; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(cc) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:60; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:26;
(dd) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:71;
(ee) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca obuhvata aminokiselinsku sekvencu SEQ ID NO:72;
(ff) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:73;
(gg) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:74;
(hh) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:75;
(ii) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:76;
(jj) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:77;
(kk) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:78; ili
(ll) varijabilna domena TCR alfa lanca sadrži aminokiselinsku sekvencu SEQ ID NO:22; i varijabilna domena TCR beta lanca sadrži aminokiselinsku sekvencu SEQ ID NO:79, i
pri čemu je anti-CD3 antitijelo kovalentno vezano za N-terminus ili C-terminus TCR beta lanca preko linkerske sekvence odabrane od SEQ ID NO: 30-37.;
8. TCR-anti CD3 fuzijska molekula prema zahtjevu 7, koja sadrži
(a) aminokiselinsku sekvencu alfa lanca koja odgovara SEQ ID NO: 38 i aminokiselinsku sekvencu beta lanca koja odgovara SEQ ID NO: 42;
(b) aminokiselinsku sekvencu alfa lanca koja odgovara SEQ ID NO: 38 i aminokiselinsku sekvencu beta lanca koja odgovara SEQ ID NO: 43;
(c) aminokiselinsku sekvencu alfa lanca koja odgovara SEQ ID NO: 39 i aminokiselinsku sekvencu beta lanca koja odgovara SEQ ID NO: 44;
(d) aminokiselinsku sekvencu alfa lanca koja odgovara SEQ ID NO: 40 i aminokiselinsku sekvencu beta lanca koja odgovara SEQ ID NO: 45; ili
(e) aminokiselinsku sekvencu alfa lanca koja odgovara SEQ ID NO: 41 i aminokiselinsku sekvencu beta lanca koja odgovara SEQ ID NO: 45.;
9. TCR-anti CD3 fuzijska molekula prema zahtjevu 7, koja sadrži aminokiselinsku sekvencu alfa lanca koja odgovara SEQ ID NO: 40 i aminokiselinsku sekvencu beta lanca koja odgovara SEQ ID NO: 45.;
10. TCR-anti CD3 fuzijska molekula prema zahtjevu 7, koji sadrži aminokiselinsku sekvencu alfa lanca koja odgovara SEQ ID NO: 38 i aminokiselinsku sekvencu beta lanca koja odgovara SEQ ID NO: 42.;
11. Nukleinska kiselina koja kodira TCR alfa lanac i TCR beta lanac prema bilo kojem od prethodnih zahtjeva.;
12. Ekspresijski vektor koji sadrži nukleinsku kiselinu prema zahtjevu 11.;
13. Ekspresijski vektor prema zahtjevu 12, naznačen time što vektor sadrži prvi otvoreni okvir čitanja koji kodira TCR alfa lanac i drugi otvoreni okvir čitanja koji kodira TCR beta lanac.;
14. Stanica u kojoj se nalazi
(a) Ekspresijski vektor prema zahtjevu 12 ili 13 koji kodira TCR alfa i beta lance prema bilo kojem od zahtjeva 1 do 10, u jednom otvorenom okviru čitanja, ili dva različita otvorena okvira čitanja; ili
(b) prvi ekspresijski vektor koji sadrži nukleinsku kiselinu koja kodira alfa lanac TCR prema bilo kojem od zahtjeva 1 do 10, i drugi ekspresijski vektor koji sadrži nukleinsku kiselinu koja kodira beta lanac TCR prema bilo kojem od zahtjeva 1 do 10.;
15. Stanica koja se ne pojavljuje u prirodi, posebno T-stanica, koja prikazuje TCR prema bilo kojem od zahtjeva 1 do 6.;
16. Farmaceutska kompozicija koja sadrži TCR prema bilo kojem od zahtjeva 1-6, TCR-anti CD3 fuzijska molekula prema zahtjevima 7-10, nukleinsku kiselinu prema zahtjevu 11, i/ili stanicu prema zahtjevu 14 ili zahtjevu 15, zajedno sa jednim ili više farmaceutski prihvatljivih nosača ili ekscipijenasa.;
17. TCR prema bilo kojem od zahtjeva 1 do 6, TCR-anti-CD3 fuzijska molekula prema zahtjevima 7-10, nukleinska kiselina prema zahtjevu 11, farmaceutska kompozicija prema zahtjevu 16 i/ili stanica prema zahtjevu 14 ili 15, za upotrebu u leku.;
18. TCR, TCR-anti-CD3 fuzijska molekula, nukleinska kiselina, farmaceutska kompozicija i/ili stanica za upotrebu prema zahtjevu 17, pri čemu je TCR, TCR-anti-CD3 fuzijska molekula, nukleinska kiselina, farmaceutska kompozicija ili stanica za upotrebu u postupku liječenja raka ili tumora, poželjno kod humanog subjekta.;
19. TCR, TCR-anti-CD3 fuzijska molekula, nukleinska kiselina, farmaceutska kompozicija i/ili stanica za upotrebu prema zahtjevu 18, pri čemu (i) humani subjekat ima tumor koji eksprimira MAGE A4, (ii) tumor je solidni tumor, (iii) humani subjekat je podtipa HLA-A*02 i/ili (iv) TCR, TCR-anti-CD3 fuzijska molekula, nukleinska kiselina, farmaceutska kompozicija ili stanica se primjenjuju injekcijom, kao što je intravenska ili direktna intratumoralna injekcija.
20. Postupak za proizvodnju TCR prema bilo kojem od zahtjeva 1 do 6, ili TCR-anti-CD3 fuzijske molekule prema bilo kojem od zahtjeva 7 do 10, koji sadrži a) održavanje stanice prema zahtjevu 14 pod optimalnim uvjetima za ekspresiju TCR lanaca i b) izoliranje TCR lanaca.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201606009 | 2016-04-08 | ||
EP17717845.6A EP3440105B1 (en) | 2016-04-08 | 2017-04-07 | T cell receptors |
PCT/GB2017/050985 WO2017175006A1 (en) | 2016-04-08 | 2017-04-07 | T cell receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220865T1 true HRP20220865T1 (hr) | 2022-10-14 |
Family
ID=58548761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220865TT HRP20220865T1 (hr) | 2016-04-08 | 2017-04-07 | T stanični receptori |
Country Status (29)
Country | Link |
---|---|
US (2) | US11505590B2 (hr) |
EP (2) | EP3440105B1 (hr) |
JP (1) | JP7254519B2 (hr) |
KR (1) | KR102473964B1 (hr) |
CN (1) | CN109563148B (hr) |
AU (2) | AU2017246693B2 (hr) |
BR (1) | BR112018070741A2 (hr) |
CA (1) | CA3020214A1 (hr) |
CL (1) | CL2018002859A1 (hr) |
CO (1) | CO2018011972A2 (hr) |
CR (1) | CR20180531A (hr) |
DK (1) | DK3440105T3 (hr) |
ES (1) | ES2914648T3 (hr) |
HR (1) | HRP20220865T1 (hr) |
HU (1) | HUE059159T2 (hr) |
IL (2) | IL262144B2 (hr) |
LT (1) | LT3440105T (hr) |
MA (1) | MA44608B1 (hr) |
MD (1) | MD3440105T2 (hr) |
MX (1) | MX2018012318A (hr) |
MY (1) | MY198621A (hr) |
PE (2) | PE20190335A1 (hr) |
PH (1) | PH12018502158A1 (hr) |
PL (1) | PL3440105T3 (hr) |
PT (1) | PT3440105T (hr) |
RS (1) | RS63371B1 (hr) |
SG (1) | SG11201808797XA (hr) |
SI (1) | SI3440105T1 (hr) |
WO (1) | WO2017175006A1 (hr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4389898A2 (en) * | 2016-04-08 | 2024-06-26 | Adaptimmune Ltd | T cell receptors |
MX2018012268A (es) * | 2016-04-08 | 2019-02-07 | Adaptimmune Ltd | Receptores de celulas t. |
EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2019133443A1 (en) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Modified t cell receptors |
GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
MX2020010459A (es) * | 2018-04-05 | 2021-01-20 | Juno Therapeutics Inc | Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas. |
JP2022523290A (ja) | 2019-01-17 | 2022-04-22 | イムノコア リミテッド | 製剤 |
GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
US20220324939A1 (en) * | 2019-06-18 | 2022-10-13 | Regeneron Pharmaceuticals, Inc. | Mage-a4 t cell receptors and methods of use thereof |
CN114245807A (zh) | 2019-06-25 | 2022-03-25 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
AU2020406085A1 (en) | 2019-12-18 | 2022-05-26 | F. Hoffmann-La Roche Ag | Antibodies binding to HLA-A2/MAGE-A4 |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
WO2021236548A1 (en) * | 2020-05-18 | 2021-11-25 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
WO2021236638A1 (en) * | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
KR20230169944A (ko) | 2021-03-09 | 2023-12-18 | 씨디알-라이프 아게 | Mage-a4 펩티드-mhc 항원 결합 단백질 |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
TW202328212A (zh) | 2021-12-01 | 2023-07-16 | 英商英美偌科有限公司 | Mage—a4陽性癌症之治療 |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
CN117106060A (zh) * | 2022-05-17 | 2023-11-24 | 香雪生命科学技术(广东)有限公司 | 一种识别mage的高亲和力t细胞受体及其应用 |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038165A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
US20240091262A1 (en) * | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6685698A (en) | 1997-03-07 | 1998-09-22 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
KR100712256B1 (ko) | 1997-10-02 | 2007-04-27 | 알토 바이오사이언스 코포레이션 | 가용성 단일쇄 t-세포 수용체 단백질 |
US6710172B1 (en) * | 1998-10-02 | 2004-03-23 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
EP2287185A3 (en) | 1999-12-06 | 2012-10-10 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
WO2001062908A2 (en) | 2000-02-22 | 2001-08-30 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
WO2004023973A2 (en) * | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
DE60327795D1 (de) | 2002-11-09 | 2009-07-09 | Immunocore Ltd | T zell rezeptor "display" |
GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
ES2599010T3 (es) | 2005-04-01 | 2017-01-31 | Immunocore Ltd. | Receptores de linfocitos T con alta afinidad por el VIH |
WO2007032255A1 (ja) | 2005-09-13 | 2007-03-22 | Mie University | T細胞レセプター及び該レセプターをコードする核酸 |
GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
PT2755997T (pt) | 2011-09-15 | 2018-10-30 | Us Health | Recetores de célula t que reconhecem mage restrito a hlaa1 ou hla-cw7 |
SG11201400521PA (en) | 2011-10-14 | 2014-08-28 | Teva Pharmaceuticals Australia Pty Ltd | ANTIBODIES TO CD1d |
JP6254528B2 (ja) | 2011-10-28 | 2017-12-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 遺伝子改変t細胞受容体マウス |
GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
SI2951202T1 (sl) * | 2013-01-29 | 2020-08-31 | Max Delbrueck Centrum fuer Molekulare Medizin (MDC) Berlin-Buch | Vezavne molekule z visoko avidnostjo, ki prepoznajo mage-A1 |
ES2746240T3 (es) | 2013-03-13 | 2020-03-05 | Health Research Inc | Composiciones y procedimientos para la utilización de receptores de células T recombinantes para el reconocimiento directo de un antígeno tumoral |
WO2016007570A2 (en) * | 2014-07-09 | 2016-01-14 | The Regents Of The University Of California | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof |
WO2016022400A1 (en) | 2014-08-04 | 2016-02-11 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
PE20171653A1 (es) | 2015-04-13 | 2017-11-13 | Pfizer | Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b |
FI3430030T3 (fi) | 2016-03-16 | 2024-01-16 | Immatics Biotechnologies Gmbh | Transfektoituja t-soluja ja t-solureseptoreita käytettäviksi syöpien immunoterapiassa |
CU20180121A7 (es) | 2016-04-01 | 2019-05-03 | Kite Pharma Inc | Receptores de antígenos quiméricos y células t |
-
2017
- 2017-04-07 SG SG11201808797XA patent/SG11201808797XA/en unknown
- 2017-04-07 PE PE2018001971A patent/PE20190335A1/es unknown
- 2017-04-07 PE PE2023002239A patent/PE20240693A1/es unknown
- 2017-04-07 HR HRP20220865TT patent/HRP20220865T1/hr unknown
- 2017-04-07 EP EP17717845.6A patent/EP3440105B1/en active Active
- 2017-04-07 US US16/092,174 patent/US11505590B2/en active Active
- 2017-04-07 CN CN201780035758.0A patent/CN109563148B/zh active Active
- 2017-04-07 MA MA44608A patent/MA44608B1/fr unknown
- 2017-04-07 HU HUE17717845A patent/HUE059159T2/hu unknown
- 2017-04-07 CR CR20180531A patent/CR20180531A/es unknown
- 2017-04-07 WO PCT/GB2017/050985 patent/WO2017175006A1/en active Application Filing
- 2017-04-07 MY MYPI2018001690A patent/MY198621A/en unknown
- 2017-04-07 DK DK17717845.6T patent/DK3440105T3/da active
- 2017-04-07 RS RS20220652A patent/RS63371B1/sr unknown
- 2017-04-07 IL IL262144A patent/IL262144B2/en unknown
- 2017-04-07 MX MX2018012318A patent/MX2018012318A/es unknown
- 2017-04-07 EP EP21211000.1A patent/EP4023668A1/en active Pending
- 2017-04-07 BR BR112018070741-4A patent/BR112018070741A2/pt unknown
- 2017-04-07 KR KR1020187032374A patent/KR102473964B1/ko active IP Right Grant
- 2017-04-07 SI SI201731151T patent/SI3440105T1/sl unknown
- 2017-04-07 JP JP2018552859A patent/JP7254519B2/ja active Active
- 2017-04-07 IL IL308831A patent/IL308831A/en unknown
- 2017-04-07 CA CA3020214A patent/CA3020214A1/en active Pending
- 2017-04-07 PL PL17717845.6T patent/PL3440105T3/pl unknown
- 2017-04-07 AU AU2017246693A patent/AU2017246693B2/en active Active
- 2017-04-07 PT PT177178456T patent/PT3440105T/pt unknown
- 2017-04-07 MD MDE20190184T patent/MD3440105T2/ro unknown
- 2017-04-07 LT LTEPPCT/GB2017/050985T patent/LT3440105T/lt unknown
- 2017-04-07 ES ES17717845T patent/ES2914648T3/es active Active
-
2018
- 2018-10-08 CL CL2018002859A patent/CL2018002859A1/es unknown
- 2018-10-08 PH PH12018502158A patent/PH12018502158A1/en unknown
- 2018-11-02 CO CONC2018/0011972A patent/CO2018011972A2/es unknown
-
2022
- 2022-10-13 US US18/046,408 patent/US20230322895A1/en active Pending
- 2022-10-19 AU AU2022256131A patent/AU2022256131A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220865T1 (hr) | T stanični receptori | |
HRP20230542T1 (hr) | T stanični receptori | |
HRP20221021T1 (hr) | T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02 | |
US11084862B2 (en) | T cell receptors | |
RU2018138837A (ru) | Т-клеточные рецепторы | |
CA2566363C (en) | High affinity ny-eso t cell receptor | |
RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
HRP20231645T1 (hr) | T stanični receptori | |
HRP20190472T4 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
BR112020000762A2 (pt) | anticorpo de dupla especificidade, moléculas polipeptídicas, ácido nucleico, célula hospedeira, composição farmacêutica e método de tratamento de uma doença ou condição | |
RU2018138836A (ru) | Т-клеточные рецепторы | |
HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
CA2516702A1 (en) | Modified t cell receptor linked by disulphide bond between constant domain cysteine residues | |
JP2017526361A5 (hr) | ||
JP2006502741A5 (hr) | ||
Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
HRP20221375T1 (hr) | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka | |
JP2019515653A5 (hr) | ||
CN106459178B (zh) | 针对rhamm抗原短肽的高亲和力t细胞受体 | |
JP2018506287A5 (hr) | ||
EP3299389A1 (en) | Soluble and stable heterodimeric tcr | |
JPWO2020024915A5 (hr) | ||
WO2023241391A1 (zh) | 一种结合ssx2抗原的tcr分子及其应用 | |
WO2023246911A1 (zh) | 基于t细胞受体的双特异性多肽分子及其用途 | |
RU2022116808A (ru) | Т-клеточные рецепторы |